| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical and Translational Research |
| Article Title |
Transcriptome changes in stages of non-alcoholic fatty liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jihad Aljabban, Michael Rohr, Saad Syed, Kamal Khorfan, Vincent Borkowski, Hisham Aljabban, Michael Segal, Mohamed Mukhtar, Mohammed Mohammed, Maryam Panahiazar, Dexter Hadley, Ryan Spengler and Erin Spengler |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jihad Aljabban, MD, MSc, Academic Research, Doctor, Doctor, Department of Medicine, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, United States. jaljabban@uwhealth.org |
| Key Words |
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Bioinformatics; AKT inhibitor; Therapy |
| Core Tip |
Our results from the NAFLD analysis reinforce the role of altered metabolism, inflammation, and cell survival in pathogenesis and support recently described contributors to disease activity, such as altered androgen and lncrna activity. The top upstream regulator was found to be SREBF1, a transcription factor involved in lipid homeostasis. Downstream of SREBF1, we observed upregulation in CXCL10, HMGCR, HMGCS1, FABP5, PEG10, and downregulation of SHBG and IGF1. These molecular changes reflect low-grade inflammation secondary to accumulation of fatty acids in the liver. Our results from the NASH analysis emphasized the role of cholesterol in pathogenesis. Top upstream regulators included pro-inflammatory cytokines TNF and IL1B, PDGF BB, and beta-estradiol. Inhibition of beta-estradiol was shown to be related to derangement of several cellular downstream processes including metabolism, extracellular matrix deposition, and tumor suppression. Lastly, we found riciribine (an AKT inhibitor) and ZSTK-474 (a PI3K inhibitor) as potential drugs that targeted the differential gene expression in our dataset. |
| Publish Date |
2022-07-27 13:17 |
| Citation |
Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H, Segal M, Mukhtar M, Mohammed M, Panahiazar M, Hadley D, Spengler R, Spengler E. Transcriptome changes in stages of non-alcoholic fatty liver disease. World J Hepatol 2022; 14(7): 1382-1397 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i7/1382.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i7.1382 |
